MODD News & Events

Modular Medical announced the start of production of validation lots for its Pivot tubeless patch pump's disposable cartridge and infusion set. Achievement of this manufacturing milestone keeps the Company on schedule for commercial launch in Q1 2026, subject to receipt of FDA 510(k) clearance. "We are excited to hit this pivotal manufacturing validation on schedule, bringing us closer to delivering our Pivot pump's game-changing simplicity to patients underserved by current options," said Jeb Besser, CEO. "This further derisks our expected path to Q1 2026 commercialization, which is subject to FDA response to our current 510(k) application, and would put us in position to drive market disruption."

Modular Medical announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. The shares of the common stock and the accompanying warrants are immediately separable and will be issued separately but can only be purchased together in this offering. Newbridge Securities Corporation is acting as the sole bookrunner for the proposed offering.

Modular Medical announced Institutional Review Board approval to conduct an in-house study of its next-generation Pivot insulin delivery system using insulin on people with diabetes. Pursuant to U.S. Food and Drug Administration regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback. Modular Medical's Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion. Key objectives and potential impacts of the Study include: Assess usability and the patient experience. Collect participant feedback to optimize design for everyday diabetes management